A cost-effectiveness analysis of introducing pneumococcal vaccine in the Swedish vaccination programme
This study was commissioned by the National Board of Health and Welfare as part of an evaluation regarding if the pneumococcal vaccine should be included in the national vaccination programme for children. Early in the process of this evaluation it was recognised that while data existed on many of the aspects of the vaccine that needed to be evaluated, no data existed on the health-economic impacts of the introduction of the vaccine in Sweden. The study provided a valuable input in the final decision to include the vaccine in the national programme. The study was made by The Swedish Institute for Health Economics in Lund, Sweden.